Enovis Corporation (NYSE:ENOV) Receives $41.71 Average Target Price from Brokerages

Shares of Enovis Corporation (NYSE:ENOV) have been assigned an average rating of “Moderate Buy” from the ten ratings firms that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $41.7143.

ENOV has been the subject of a number of recent research reports. William Blair began coverage on shares of Enovis in a report on Friday, April 17th. They issued an “outperform” rating for the company. Weiss Ratings raised shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. BTIG Research reiterated a “buy” rating and issued a $39.00 target price on shares of Enovis in a research report on Friday, May 22nd. BMO Capital Markets started coverage on shares of Enovis in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $29.00 price target for the company. Finally, Evercore set a $32.00 price target on shares of Enovis in a research report on Monday, July 6th.

Insider Buying and Selling at Enovis

In related news, insider Oliver Engert bought 1,200 shares of the stock in a transaction dated Thursday, June 11th. The stock was bought at an average price of $21.62 per share, with a total value of $25,944.00. Following the purchase, the insider owned 51,840 shares in the company, valued at approximately $1,120,780.80. The trade was a 2.37% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Over the last three months, insiders bought 4,200 shares of company stock valued at $92,084. Insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP boosted its holdings in Enovis by 1.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company’s stock worth $90,156,000 after acquiring an additional 51,201 shares in the last quarter. Rubric Capital Management LP bought a new stake in Enovis during the third quarter valued at about $83,435,000. Paradigm Capital Management Inc. NY lifted its holdings in shares of Enovis by 70.2% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after acquiring an additional 732,917 shares during the last quarter. River Road Asset Management LLC boosted its stake in shares of Enovis by 3.2% during the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock worth $39,621,000 after purchasing an additional 46,289 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of Enovis by 38.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company’s stock worth $24,430,000 after purchasing an additional 287,687 shares during the period. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis Price Performance

ENOV stock opened at $27.05 on Friday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The business has a 50-day simple moving average of $23.65 and a two-hundred day simple moving average of $23.76. The company has a market capitalization of $1.56 billion, a P/E ratio of -1.36 and a beta of 1.39. Enovis has a 52-week low of $19.14 and a 52-week high of $34.28.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The firm had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. During the same period in the prior year, the business posted $0.81 earnings per share. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Research analysts expect that Enovis will post 3.12 EPS for the current fiscal year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.